Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity. The oncologists examined deveral pivotal trials ...

Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...

CLEVELAND, March 10, 2026 /PRNewswire/ -- Oncologists currently have limited tools to predict which lung cancer patients will benefit from immunotherapy. The publication of a multi-institutional study ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.

Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Chemotherapy and radiation are common treatments for lung cancer. However, immunotherapy may be able to help double a patient's survival, according to a new report. Researchers from New York ...

Scientists, medical researchers at Case Western Reserve, NYU Langone Health and University Hospitals using machine-learning to predict response to immunotherapy Medical researchers from Case Western ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.